Establishment Labs Holdings Inc. - Common Shares (ESTA)
30.80
+0.07 (0.23%)
Establishment Labs Holdings Inc. is a medical technology company focused on developing innovative products for the aesthetic and reconstructive breast surgery market
The company specializes in breast implants and other related medical devices, emphasizing safety, quality, and advanced design to enhance patient outcomes. Through its proprietary technologies and commitment to research and development, Establishment Labs aims to address the evolving needs of healthcare professionals and patients, fostering advancements in cosmetic and reconstructive procedures. Their offerings are designed to improve both the surgical experience for practitioners and the overall satisfaction and well-being of patients.
Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness in breast aesthetics and reconstruction, announced today that after twenty years as Chief Executive Officer (CEO), Juan José Chacón-Quirós has decided to retire as CEO, effective March 1, 2025. Peter Caldini, currently President of Establishment Labs, will serve as Interim CEO after that date.
Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 3:45 p.m. Pacific Time.
Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in three upcoming investment conferences.
Establishment Labs Holdings Inc. (Nasdaq: ESTA) (the “Company”), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that it has entered into a securities purchase agreement (the “Purchase Agreement”) with select purchasers for the purchase of 765,696 common shares and pre-funded warrants to purchase up to 328,161 common shares in a registered direct offering for aggregate gross proceeds of approximately $50 million.
Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the third quarter ended September 30, 2024.
Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced the presentation of three-year clinical results with Mia Femtech™ at the 9th Annual World Symposium on Ergonomic Implants (WSEI) being held this week in Barcelona, Spain.
Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2024, after the market closes on Thursday, November 7, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results.
Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced that it has published its 2024 Post Market Surveillance (PMS) Report.
Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced today that the first patients in the United States have successfully undergone breast augmentation with Motiva® Implants.
Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced it has received approval from the U.S. Food and Drug Administration (FDA) for the use of Motiva® SmoothSilk® Ergonomix® and Motiva® SmoothSilk® Round breast implants in primary and revision breast augmentation.
ESTA stock results show that Establishment Labs Hldgs missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2024.
Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2024, after the market closes on Tuesday, August 6, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results.
June 18, 2024 - New York, NY - Findell Capital Management LLC, an investment management firm, today announced the release of a detailed Report on Establishment Labs Holdings Inc. (Nasdaq: ESTA), which can be found here .
New York, NY, June 17, 2024 – Findell Capital Management LLC, an investment management firm, today announced the release of a detailed Report on Establishment Labs Holdings Inc. (Nasdaq: ESTA), which can be found here.
Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in two upcoming investment conferences.
Establishment Labs Holdings Inc. (NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2024.
